ArticleBMC cancer2025

Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis.

Xinrong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.